One comment I had on the previous post was that the percentage of Oxford Nanopore’s revenue coming from consumables is high (75%) and that this is a good sign.
Really interesting analysis Nava, in the context of this year (2024) being the 'breakout' year for them (and PacBio) reaching over some $210M and $200M in sales apiece. Yet similar stories between both ONT and PACB...
A lot of time (founded in 2005, MinION in 2015), money (how much cash did it burn before becoming a public company?) and effort (lots of effort) only to come up with a 169M GBP sales for 2023 while the investors expected 177M GBP. That's only 5% short, however you always want to surprise to the up-side, which Illumina became somewhat famous for doing. PACB also disappointed.
It's a game of setting expectations and then beating them, which is really hard to do.
Really interesting analysis Nava, in the context of this year (2024) being the 'breakout' year for them (and PacBio) reaching over some $210M and $200M in sales apiece. Yet similar stories between both ONT and PACB...
A lot of time (founded in 2005, MinION in 2015), money (how much cash did it burn before becoming a public company?) and effort (lots of effort) only to come up with a 169M GBP sales for 2023 while the investors expected 177M GBP. That's only 5% short, however you always want to surprise to the up-side, which Illumina became somewhat famous for doing. PACB also disappointed.
It's a game of setting expectations and then beating them, which is really hard to do.